New anti-epileptic drugs differ from existing standard therapies not in their clinical efficacy, but in their side-effects profiles. To determine the relative economic value of these agents, one must compare drug costs, costs of resources employed in the management of adverse events, and costs associated with therapeutic switching. In this economic analysis, carbamazepine (CBZ) and lamotrigine (LTG) are evaluated in monotherapy treatment of partial and/or general tonic-clonic seizures in the UK. Adverse event and tolerability data are obtained from a published randomized controlled trial of CBZ vs. LTG. A Delphi panel of clinicians advised treatment patterns for adverse events. Cost data are obtained from public sources. Results show that CBZ therapy costs about one-third of LTG therapy (£179 for CBZ vs. £522 for LTG) even after the costs associated with the management of adverse events and therapeutic switching are considered.
INTRODUCTION
The current environment of cost consciousness in health care has resulted in a need for economic evaluations of pharmaceuticals in order to identify those which provide the most value for money in treating patients. Thus, for conditions in which several competing drugs exist, economic analysis comparing the costs and outcomes of treatment with those drugs are becoming the norm.
In the area of epilepsy, the appearance of new anti-epileptic drugs (AEDs) has also stimulated economic analyses to compare the costs and outcomes of using either new or established AEDs. Where improved efficacy cannot be shown, economic evaluations must measure the 'resource implications of differing adverse-event profiles to assess the justification for higher prices,
To assist in the choice of the most appropriate AED for initial therapy, an economic evaluation has been conducted which compares carbamazepine (CBZ) and lamotrigine (LTG). The evaluation focused on patients with newly diagnosed epilepsy who are being of generalized tonic-clonic seizures or both. The objective of this study is to evaluate whether the different rates of adverse events and the impact of changing treatment after withdrawal from treatment offset the difference in drug costs between lamotrigine and carbamazepine.
The approach used in this study is cost minimization analysis (CMA). This is appropriate when comparing the costs associated with different treatments with similar efficacy rates.
Brodie et al I demonstrated that LTG and CBZ have similar efficacy, but the overall success rate in terms of improved tolerability was better for LTG than CBZ. The analysis presented is based on the trial data reported by Brodie et al 1 . Different adverseevent profiles may also have differential impact on quality of life (QOL) for the patient, however, no appropriate data on QOL are available.
The perspective of the study is that of the UK National Health Service (NHS). The analysis considers the direct medical costs of treatment to the NHS. The disease and the treatment of adverse events associated with drug therapy may also incur patient out-of-pocket expenditures and indirect costs to society in the form of productivity losses due to absence from work. However, these costs are not included as they are difficult to quantify from the information available. A clinical-decision analytic model was developed (using an Excel spreadsheet) to calculate the annual cost of treatment with each drug. The model takes into account the cost of drug therapy, the rate and cost of adverse events and changing therapy after treatment failure (withdrawal due to adverse events). The model follows patients for 1 year: patients start therapy on either CBZ or LTG. Patients may develop side effects and either the side effects resolve or the patient withdraws and is switched to an alternative drug therapy. A graphical representation of the model is shown in Fig. 1 .
Assumptions
The following assumptions were made which are discussed further in this section.
This evaluation focuses on the resources used in the treatment of adverse events and not those used in routine care. The health-care resources used in routine care were assumed to be the same for both drugs, as no differences in efficacy were shown.
The adverse-event treatment patterns assumed that the adverse-event episodes are mutually exclusive. Total 270
(costs shown in £).
Patients who withdraw while taking CBZ are switched to sodium valproate and those taking LTG to CBZ. Anti-epileptic drug efficacy was assumed to remain similar if a patient switched drug therapy. It was also assumed that patients switched to sodium valproate would have a similar rate of adverse events as for CBZ.
Data sources
The model was based on three sources of data: clinical trial data, expert clinical opinion, and published literature. Clinical trial data were used for rates of adverse events and withdrawal. Expert opinion was used to identify treatment patterns for the adverse events reported in the trial, in the absence of primary data sources. Published literature was used to obtain cost data and ranges for sensitivity analysis.
Patient outcomes
The rates of adverse events and withdrawal rates reported by Brodie et al. were used as the basis for this economic evaluation. To our knowledge only one double-blind randomized clinical trial I has been published in which CBZ and LTG (monotherapy) are compared in patients with newly diagnosed epilepsy in the UK. This trial was a double-blind, randomized parallel group comparison, following 260 patients (aged 13 years and over) for 48 weeks. After
Economic analysis of epilepsy treatment randomization there was a period of dose escalation in which patients received increasing doses of 50 mg LTG and 200 mg of CBZ so that at 4 weeks all patients were taking either LTG 150 mg/day or CBZ 600 mg/day. This dose was maintained throughout the trial with adjustment for seizures as necessary.
Efficacy. No significant differences in the proportion of patients maintained seizure free on either drug therapy were reported in the trial.
Adverse-event
rates. The adverse-event rates for LTG and CBZ used are documented in Table 1 . The rate of sleepiness was the only adverse event which was significantly different between the two groups of patients.
Information on the severity of adverse events and their relationship to trial medication was not reported. Some of the adverse events such as rhinitis are unlikely to be related to drug therapy but are only reported because of the trial protocol.
Switching drugs after withdrawal. Withdrawal rates due to adverse events reported by Brodie et al I were used as a proxy for switching therapy. The rate of withdrawal due to adverse events was 15% in patients taking LTG and 27% in patients taking CBZ.
If a patient withdrew from drug therapy, it was assumed that the patient would switch to an alternative regimen; patients taking CBZ would be switched to sodium valproate (1000 mg/day) and patients taking LTG to CBZ (600 mg/day). It was assumed that patients would remain on this regimen for the rest of the year, with the adverse-event rates and costs of the AED to which the change was made. The choice of the alternative drug regimen was based on expert opinion of practice in the UK. In the absence of 121 suitable trial data, the efficacy rate and rate of adverse events in patients switched to sodium valproate were assumed to be similar to CBZ. Sensitivity analysis was conducted to examine the implications of switching therapy and the choice of the alternative drug regimen.
The mean time of withdrawal due to adverse events after starting a drug therapy was not reported by Brodie et al I . A mean time to withdrawal of 6 weeks was used based on clinical opinion. Sensitivity analysis was conducted to examine the impact of this parameter on the results.
Resource utilization
Costs of adverse events were developed in consultation with specialists in epilepsy care as no detailed information on the management of adverse events was available from the literature or databases. Previous economic analyses have either not examined the treatment of adverse events in detail 2 or this aspect has not been fully reported. Navarro and Ashraf 3 calculated different adverse-event treatment costs based on a physician panel; however, the additional resources utilized were not fully documented.
The expert panel consisted of four specialists in epilepsy care. A questionnaire was designed to collect information on treatment patterns and was administered by mail with telephone follow-up, where necessary. Typical treatment patterns for each adverse event were derived based on the mean value of the physician responses.
Hospital-based epilepsy specialists were the focus of this exercise and were used to estimate resource use in both the hospital and general-practice setting. Although general practitioners (GPs) provide considerable care for patients with epilepsy it was decided not to consult GPs in this case for the following reasons: the care of the newly diagnosed patient is usually the responsibility of the neurologist who would be responsible for making therapy changes, although, once the patient is stabilized on maintenance therapy he will be referred back to his GP. The average GP is unlikely to have substantial experience of treating drug-related adverse events, as he is not likely to have more than 20 patients with epilepsy. However, there may be regional variations in treatment practice, in some areas waiting time for a neurology consultation is so long that a GP may initiate treatment.
The questionnaire focused on changes in drug therapy and health-care resources utilized specifically for the adverse events. For each adverse event questions were asked to establish how the typical patient is managed; if management of the adverse event alters standard AED therapy; if management of the event 
Tests
AED levels (25%) FBC, U&Es, LTF (CBZ, 40%; LTG, 53%) Percentages in parentheses refer to the proportion of patients utilizinga particular resource. CBZ = carbamazepine, FBC = full blood count, LTG = lamotrigine, U&E = urea and electrolytes+ LFT = liver function test. resources are used to manage the adverse event, in addition to those used in routine treatment. Treatment patterns which reflect the typical pattern of care rather than 'ideal' practice were requested. The treatment patterns are based on the assumption that the patients suffers only one adverse event at a time, as no data were available on the rates of concurrent events. This may result in some double counting of resource utilization, for example, a patient suffering nausea and dizziness at the same time would probably have both adverse events managed in the same consultation.
Example of the treatment patterns for each adverse event are shown in Table 2 . The frequency of use, proportion of patients and reduction in drug doses are mean values of the estimates provided by the physicians.
Unit cost
The unit prices used to convert the treatment patterns into costs for each adverse event were based on national databases and published studies. The principal sources of data were the CIPFA database of UK NHS Economic analysis of epilepsy treatment Costs were not discounted as the time frame of the analysis is only 1 year. Drug costs were calculated using the prices for the brand-name products quoted in the British National Formulary 5. These are basic net prices to the NHS and exclude overhead allowances. The annual cost of CBZ (Tegretol) 600 mg/day was £57.45 and LMG (Lamictal) 150 mg/day was £484.54. The individual costs and sources are shown in Table 3 .
Adverse-event costs. The costs for each adverseevent episode are shown in Table 4 . They were calculated by applying the unit costs (Table 3) to the resources used (Table 2) .
Withdrawal and switching drugs. The cost of withdrawing and switching drug therapy was £72.014 , which was the cost of neurologist consultation.
Sensitivity analysis. Sensitivity analyses were conducted on key parameters: drug dose, proportion of patient switch therapy, the time of therapy switch and the choice of drug switched to.
RESULTS

Base case
The annual average costs per patient (excluding the cost of routine care) was calculated for a patient treated successfully (who did not switch therapy) with CBZ or LTG and for those who switched drug therapy. These average costs for the base case are shown in Table 5 . The average cost for a successfully treated patient includes the cost of drug therapy and treating adverse events. For those patients who switch therapy, the total annual cost includes drug costs (6-weeks treated with CBZ switched to sodium valproate for the rest of the year or LTG switched to CBZ), adverse-event costs (incurred before and after switching) and the cost of a neurology consultation for the drug switch.
The average annual cost per patient taking CBZ or LTG was calculated using a weighted average of the cost of a successful treatment and switching based on the proportion of patients in each category. The proportion of patients who switch drug therapy is 27% of patienis taking carbamazepine and 15% of patients taking lamotrigine. The average annual cost for each drug and the distribution of costs for the base case are shown in Table 6 .
The average costs for a year of treatment was £179.34 for patients taking CBZ and £521.74 for patients taking LTG. Treatment with CBZ cost £342.40 less than with LTG.
Sensitivity analysis
Sensitivity analyses were conducted on the following parameters and the results are documented in Table 7 .
UK drug doses. The results were calculated using the cost of drug therapy based on the mean daily doses of CBZ (800 mg) and LTG (250 mg) suggested by UK physicians. The drug costs for 1 year of treatment at these doses is £76.65 for CBZ and £807.56 for LTG.
Proportion of patients switching therapy. The proportion of patients who switched therapy was adjusted to 10% for CBZ patients and 4.5% for LTG to reflect the rates reported by Yuen I°. Switching drug therapy time. The mean time at which drug therapy was switched was varied from 1 to 6 months.
Drug switched to.
A sensitivity analysis was conducted in which patients taking CBZ who withdrew were switched to LTG instead of sodium valproate. This increases the average annual cost of CBZ therapy to £264.60 and decreases the difference in cost between treatment with LTG and CBZ to £257.14.
DISCUSSION
Drug costs and the cost of withdrawal are the key issues in this evaluation. The cost of treating adverse events was similar for both drugs. Drug costs account for a substantial proportion of the average cost per patient for both drugs (CBZ 40%, LTG 82%). The cost of switching primarily reflects the cost of the drug switched to. Therefore, switching drug therapy is cost saving for patients taking LTG as patients are switched to CBZ, a significantly cheaper drug. The annual cost for a patient who switches drug therapy to CBZ from LTG is £270 compared with £562 for a year of successful treatment. Sensitivity analysis demonstrated that significant cost savings (£257) remain even when patients taking CBZ initially are switch to LTG instead of valproate.
When considering the results of this economic evaluation a number of limitations must be recognized. The economic evaluation is based on one clinical trial, therefore, consideration must be given to the generalizability of this to clinical practice in the UK. Clinical trials often do not reflect real clinical practice, for example, due to the nature of trial inclusion and exclusion criteria and the reporting of adverse events. Adverse events were assumed to be mutually exclusive and treatment patterns were estimated based on this assumption. Health-care resource utilization was also assumed to be equal for both drugs except for adverse events. The adverse-event treatment patterns were based on expert opinion and these require validation, preferably using either retrospective or prospective patient data collection.
The rates of adverse event and withdrawal reported by Brodie et al I have been the subject of much discussion, which was used to guide the sensitivity analyses conducted. The adverse event rates for carbamazepine were higher than those reported in other studies, for example, the Veterans Administration cooperative studies 3. These studies did not include comparison of LTG and CBZ drug therapy so it is not possible to apply these data to this analysis. However, the rate of adverse events in patients taking CBZ would have to be over seven times greater than with LTG to offset cost differences.
The CBZ dose escalation schedule used in the Brodie trial has been criticized for not representing clinical practice 1 I. 12. It was suggested that the doseescalation schedule used in the trial is faster than the usual practice of many neurologists. This factor may account for the differences in tolerability between LTG and CBZ. Studies with slower escalation schedules have indicated lower rates of withdrawal due to adverse events in patients taking CBZ and LTG 1° ' 13 An open trial of CBZ and LTG monotherapy in patients with newly diagnosed and recurrent epilepsy reported withdrawal rates of 10.3% in patients taking CBZ and 4.3% and 4.5% in patients taking LTG (100 mg and 200 mg doses respectively). This rate of withdrawal in CBZ patients is similar to the rate observed in a pragmatic randomized trial (11% at 30 months) 13.
The formulation of CBZ used in the Brodie trial may also help to explain the adverse-event rates reported. The trial used the immediate-release formulation rather than the modified-release formulation of CBZ (Tegretol Retard). Use of the controlled-release formulation significantly reduces the rate of adverse events 5, 14 and withdrawal in the CBZ group.
Quality of life is not considered in this costminimization study and its estimation is vital where alternative therapies are associated with both bene-ficial and harmful effects. In this case, although efficacy in patients tolerating treatment is considered to be similar for the two therapies, adverse events and the process of changing therapy could have an adverse impact on QOL. If this were the case then the average QOL of patients could potentially be lower when treated with the drug causing most adverse events, but data are not available to test this hypothesis. Both the number, type and severity of adverse events will have an impact on health-related QOL. The appropriate analytic framework in which to test the importance of any QOL change would be a cost-utility study. However, information on QOL in patients with epilepsy is limited 15 and appropriate QOL data are not available to evaluate the impact of different AED therapies.
CONCLUSIONS
The results of this evaluation indicate that under basecase assumptions treatment with CBZ is cost saving when compared with LTG as monotherapy in patients with newly diagnosed epilepsy. The average cost per patient treated with CBZ (£179.34) is 34% of the average cost of treatment with LTG (£521.74). The costs of adverse events and switching therapy do not offset the additional cost of LTG therapy. In sensitivity analysis the results appear robust under changing circumstances. The results of this study are supported by the US analysis conducted by Navarro and Ashraf 3. Based on their calculation of adverse-events costs, similar cost savings with CBZ treatment would be expected. Health-care providers and purchasers need to consider whether the advantages in tolerability reported by Brodie et a/l justify an addition £342 per patient annual cost for treatment with LTG.
